Kadmon Holdings, LLC Launches IPO
The Aeon Fund Team is pleased to announce that as of 7:52AM this morning, Kadmon Holdings LLC filed their S-1 with the SEC.
Kadmon Holdings is a fully integrated biopharmaceutical company that develops products addressing the following diseases: autoimmune and fibrotic, oncological, and genetic. With Kadmon’s multi-disciplinary approach, the company has developed a series of products and drug pipelines to combat serious and rare diseases.
The IPO is filed to offer up to $115,000,000 in common stock as well as $25,000,000 in convertible term loans for a total of $140,000,000.